
11 of June 2024

WHITE PAPER: TOKENIZATION OF PROTEIN PRODUCTS



IMAGO ENGINEERING SDN. BHD.
info@imagoengineering.com
www.imagoengineering.com

Contents

1.	DEFINITIONS	2
2.	ABSTRACT	2
3.	INTRODUCTION.....	2
4.	PROBLEM STATEMENT	2
5.	BACKGROUND.....	3
6.	SOLUTION	4
7.	CASE STUDIES AND SUCCESSFUL EXAMPLES.....	6
8.	FEATURES AND USE CASES	6
9.	TOKENOMICS	8
10.	TECHNOLOGY.....	10
11.	MARKET ANALYSIS	11
12.	ROADMAP	14
13.	TEAM.....	16
14.	CONCLUSION	18
15.	LEGAL STATEMENTS AND NOTICES	20
16.	REFERENCES.....	25

1. DEFINITIONS

In this White Paper, the following words and expressions have the following meanings unless the context otherwise requires:

- **"IMAGO"**: Refers to Imago Engineering Sdn. Bhd., registered in Malaysia, registration Number: 202201023318 (1469015-A)
- **"IEProtein"**: IMAGO tokens described in this White Paper.
- **"Product"**: Feed protein for animals, poultry, and aquaculture, sold by Imago Engineering SDN. BHD.
- **"USD"**: United States Dollar, the currency reference.
- **"White Paper"**: This document outlining the process and benefits of tokenizing product - protein by IMAGO Engineering SDN BHD.

2. ABSTRACT

This document describes the process of tokenizing the protein product by Imago Engineering SDN BHD (IMAGO). Tokenization allows holders of IEProtein tokens to exchange them for the product — Protein, the price of which is pegged to the market price of 1 kg of protein sold by Imago Engineering SDN BHD. The minimum exchange quantity is 1 kg. The purpose of this White Paper is to explain how tokenization will enhance customer interaction, streamline processes, and provide new opportunities for consumers.

3. INTRODUCTION

Tokenization of products opens new business opportunities by providing consumers with an innovative way to interact with the company's products. This White Paper provides a detailed examination of the protein product tokenization process and its benefits for all participants.

4. PROBLEM STATEMENT

4.1 Problem

The modern market requires more transparent and secure methods of trading and exchanging products. Traditional methods of interaction can be inefficient and costly. Tokenization offers a solution to improve these processes, especially when it comes to agricultural products such as protein:

4.1.1 Opaque Processes

Traditional trading methods do not always ensure transparency for all supply chain participants, which can lead to mistrust between producers and consumers. [1]

4.1.2 High Transaction Costs

Current methods of trading and exchange often involve high transaction costs, including intermediary fees, commissions, and logistics expenses. [3]

4.1.3 Limited Liquidity

Agricultural products like protein have limited liquidity, making them difficult to sell and exchange. [2]

4.1.4 Quality Tracking Challenges

The lack of a clear system for tracking and controlling product quality can lead to doubts about its safety and health benefits.

4.2 Relevance of the Problem to the Target Audience

Protein producers and consumers face issues such as counterfeiting, supply chain management difficulties, low product quality, and lack of transparency. Tokenization addresses these problems by ensuring traceability, protection against counterfeits, reducing operational risks, and providing complete product information. This enhances consumer trust and loyalty, creating a more transparent and efficient trading system beneficial for all market participants. Tokenization improves the transparency, reliability, and efficiency of trading, positively impacting all market participants. [1] [2] [3]

5. BACKGROUND

5.1 Current Situation

With the growing population and increasing interest in a healthy lifestyle, the demand for alternative feed protein sources, such as insects, is significantly rising. Insect protein is gaining popularity due to its high nutritional value, low production cost, and reduced environmental impact compared to traditional feed protein sources. [7] [8]

5.1.1 Growing Demand

Consumers are becoming more aware of the benefits of insect protein: high nutritional value (over 50% of crude protein), environmental sustainability, and economic advantages. Insects require fewer resources and produce a smaller carbon footprint compared to traditional livestock, providing stable and predictable supplies. [6]

5.1.2 Environmental Benefits

Producing insect protein requires significantly fewer resources, such as water and land, compared to traditional animal and plant protein production. This makes it a sustainable and environmentally friendly choice. Reduced greenhouse gas emissions and lower environmental pollution make this type of protein preferable for many eco-conscious consumers. [8]

5.1.3 Economic Advantages

- **Supply Stability:** Independence from fish catch fluctuations and seasonal changes.
- **Reduced Logistics Costs:** Local insect farming lowers transportation expenses.
- **Raw Material Cost:** Independence from imported components.
- **Processing Time:** 3 days instead of 15, reducing capital and operational expenses. [12]

5.1.4 Production Innovations

Modern technologies, such as bioreactors and automated systems, enable the industrial-scale production of insect protein with minimal costs and environmental impact. The use of bioreactors shortens the production cycle from 15 to 3 days. [12]

5.1.5 Regulatory Recognition

In some countries, insect protein has already received regulatory recognition for use in food products and animal feed. This opens new opportunities for companies in this sector and supports market growth. [10]

5.2 Challenges and Issues

5.2.1 Consumer Perception

Despite the advantages, many consumers remain sceptical about the idea of consuming insect protein. This requires active efforts in consumer education and awareness.

5.2.2 Regulatory Barriers

In some countries, legislation on the production and consumption of insect protein is still underdeveloped, creating certain challenges for companies.

5.2.3 Competition

The market for alternative protein sources is becoming increasingly competitive, and companies must continuously innovate and improve their products to stay at the forefront.

Thus, the tokenization of protein products is an innovative solution that can help overcome many of these challenges by providing consumers with a transparent and secure way to exchange IEProtein tokens for real products. This not only improves current processes but also opens new business opportunities.

6. SOLUTION

6.1 Detailed Description of the Proposed Solution

6.1.1 Token-to-Product Linkage

Within the IMAGO project, it is proposed to peg IEProtein tokens to the Protein product sold by IMAGO. One (1) IEProtein token will be equivalent to one (1) kg of protein. The rate of 1 kg of protein is pegged to the market price set by IMAGO for its protein. IMAGO does not intend for the IEProtein token to be used for investment purposes. At the time of issuance of IEProtein tokens, the price of 1 kg of Protein is 2 USD, which means that on the issuance date, 1 IEProtein token is worth 2 USD.

6.1.2 Target Audience

IEProtein tokens are intended for customers interested in protein for use in animal feed for poultry and aquaculture. This includes animal feed manufacturers, aquaculture, poultry, and pork producers, among others.

6.1.3 Token-to-Product Exchange

Holders of IEProtein tokens will be able to exchange them for protein by visiting our office and requesting the desired quantity of protein. One (1) IEProtein token will be equivalent to one (1) kg of protein. The price of the IEProtein token will increase proportionally to the price increase of 1 kg of Protein by IMAGO, providing IEProtein token holders with protection against inflation and growth in the value of their assets.

6.1.4 Minimum Exchange Quantity

The minimum quantity of protein for exchange is 1 kg, equivalent to 1 IEProtein token.

6.1.5 Company Obligations

If IEProtein token holder requests an exchange for protein, but IMAGO cannot fulfil the exchange at the time of the request, IMAGO is obligated to complete the exchange within 6 months from the date of the request. This condition provides IEProtein token holders with confidence that they will receive their protein even in the case of a temporary shortage.

6.2 Justification for the Effectiveness of the Proposed Methods

6.2.1 Transparency and Security

The use of blockchain technology for tokenization ensures full transparency of all transactions and protection against fraud. All transactions are recorded in an open ledger, allowing for tracking of token movement and eliminating the possibility of double spending. Transaction transparency increases clients and partners trust in IMAGO and the protein.

6.2.2 Inventory Management and Logistics

The obligation to fulfil the delivery in exchange for IEProtein tokens within 6 months of the request simplifies inventory and logistics management, provides flexibility in managing production capacities, and allows for better production planning.

6.2.3 Protection Against Inflation and Supply Disruptions

Linking IEProtein token value to the market price of protein provides protection against inflation and the potential growth of asset value. The transparency of production processes and the ability to exchange tokens for finished products allows token-holding consumers to reduce the impact of market volatility.

7. CASE STUDIES AND SUCCESSFUL EXAMPLES

7.1 Ambrosus

Ambrosus uses blockchain technology to ensure transparency and track the quality of food products. Their system allows consumers and producers to monitor the origin and condition of products at every stage of the supply chain. The application of blockchain technology in the food industry has already proven effective, increasing consumer trust and improving supply chain management.

7.2 Provenance

Provenance uses blockchain technology to ensure transparency and authenticity of products, from the farm to the end consumer. Their system allows tracking the origin and quality of products, which increases consumer trust and loyalty. The application of blockchain technology has enabled Provenance to reduce the number of counterfeits and improve logistics management.

7.3 Blockchain and Tokenization

These examples demonstrate how blockchain and tokenization can be successfully applied in various industries to enhance transparency, security, and efficiency. The application of these technologies in IMAGO will allow IMAGO to achieve similar results and provide IMAGO clients and partners with a new level of trust and security.

8. FEATURES AND USE CASES

8.1 Features of Protein Product Tokenization

8.1.1 Real Product Backed Tokens

Each IEProtein token is equivalent to 1 kg of protein. This ensures transparency and simplicity for users and partners. IEProtein tokens can be easily exchanged for the actual product provided by IMAGO.

8.1.2 Flexible and Transparent Exchange

IEProtein token holders can exchange their tokens for protein by visiting the IMAGO's office. This makes the process transparent and convenient, eliminating the need for intermediaries and additional costs.

8.1.3 Transparent Pricing Structure

The value of IEProtein token is directly linked to IMAGO price of 1 kg of protein. At the time of IEProtein token issuance, 1 kg of protein costs 2 USD, making 1 IEProtein token equal to 2 USD. This linkage ensures stability and predictability in IEProtein token value.

8.1.4 Minimum Exchange Requirements

The minimum quantity of protein for exchange is 1 kg, which is equivalent to 1 IEProtein token.

8.1.5 Commitment to Fulfill Obligations

If IMAGO cannot immediately fulfil the exchange for protein, it commits to doing so within 6 months from the date of the physical request made at the IMAGO office. This condition ensures IEProtein token holders have confidence in the future possibility of exchange.

8.2 Use Cases for Tokens

8.2.1 Long-term Store of Value

IEProtein token holders can use them for long-term value retention, knowing they can exchange their tokens for the actual product in the future. This is particularly relevant in times of inflation and market instability.

8.2.2 Alternative Means of Payment

IEProtein token can be used as an alternative means of payment for purchasing protein. This can be particularly useful for large buyers, such as animal feed manufacturers, who can pre-purchase IEProtein tokens at the current price and use them to buy products as needed.

8.2.3 Customer Loyalty Programs

IEProtein token can be part of customer loyalty programs. Customers can earn tokens for purchases and use them for discounts or free protein. This encourages repeat purchases and strengthens customer relationships.

8.3 Real Use Examples

8.3.1 Example 1: Intermediary

An intermediary purchases IEProtein tokens for 10,000 USD (equivalent to 5,000 tokens, where each IEProtein token is valued at 2 USD at current rate). After a year, the price of protein increases to 3 USD per kilogram, and the price of IEProtein tokens rises to 3 USD per IEProtein token. The intermediary, by exchanging their IEProtein tokens for 5 tons of protein and selling this protein at the market price, can earn additional profit.

8.3.2 Example 2: Animal Feed Manufacturer

An animal feed manufacturer pre-purchases 50,000 IEProtein tokens at the current price (100,000 USD). As needed, they exchange IEProtein tokens for protein to produce feed, avoiding market price fluctuations and ensuring stability in their operations.

8.3.3 Example 3: Customer Loyalty Program

Customers earn IEProtein tokens for purchase of IMAGO protein. Accumulating a certain number of IEProtein tokens, they can exchange them for protein or use them for discounts on future purchases. This stimulates repeat purchases and increases customer loyalty to the brand.

These features and use cases demonstrate how the tokenization of protein products can enhance customer interaction, increase the attractiveness of partnering with IMAGO, and ensure stability and transparency of processes for all participants.

9. TOKENOMICS

9.1 Detailed Description of the Project's Financial System

The financial system of the project is based on IEProtein tokens linked to the value of IMAGO protein. The key aspects of the financial system include:

9.1.1 Token Value Linked to Real Products

One (1) IEProtein token will be equivalent to one (1) kg of protein. At the time of issuance of IEProtein tokens, the price of 1 kg of Protein is 2 USD, which means that on the issuance date, 1 IEProtein token is worth 2 USD. The price of the IEProtein token will increase proportionally to the price increase of 1 kg of Protein by IMAGO, providing IEProtein token holders with protection against inflation and growth in the value of their assets.

As part of the tokenization described in this White Paper, 7,000,000 (seven million) IEProtein tokens will be issued, which can be exchanged for 7,000,000 (seven million) kg of protein.

9.1.2 IEProtein Token Distribution Structure

- **Token Issuance:** A specified number of IEProtein tokens will be issued and distributed among various IMAGO project participants.
- **Unregulated Sale via Exchange:** A portion of the IEProtein tokens will be sold during the initial placement for unregulated sale via exchange.
- **Company Reserve:** A certain portion of IEProtein tokens will be reserved for the IMAGO operational needs, employee incentive programs, etc.
- **Rewards and Bonuses:** IEProtein tokens may be used to reward partners and clients within loyalty programs.

9.1.3 IEProtein Token Usage

- **Exchange for Products:** IEProtein token holders can exchange their IEProtein tokens for the protein at the rate of 1 IEProtein token = 1 kg of protein.
- **Sale on the Secondary Market:** IEProtein tokens can be sold on the secondary market, providing customers with the opportunity to profit from the increase in IEProtein token value.

9.2 Principles of IEProtein Token Distribution and Usage

9.2.1 Initial IEProtein Token Distribution

- **Unregulated Sale via Exchange:** 50% of all IEProtein tokens will be sold during the unregulated sale via exchange. This will create a new sales option for IMAGO clients and partners, ensuring faster IMAGO development.

- **Company Reserve:** 25% of IEProtein tokens will be reserved for company use in operational activities, including infrastructure development and marketing campaigns.
- **Team and Advisors:** 15% of IEProtein tokens will be allocated to the IMAGO team and advisors, ensuring motivation and support for the project.
- **Bonus Programs:** 5% of IEProtein tokens will be allocated for IMAGO client and partner rewards within loyalty programs.
- **Contingency Reserve:** 5% of IEProtein tokens will be reserved to cover unforeseen expenses and ensure project stability.
- **Right to Amend the Structure of the Initial Distribution of IEProtein Tokens:** IMAGO reserves the right to amend the distribution structure of IEProtein tokens.

9.2.2 IEProtein Token Utilization Mechanisms

- **Exchange for Products:** IEProtein tokens can be exchanged for protein at the IMAGO office. The minimum exchange volume is 1 kg of protein (1 IEProtein token).
- **Sale on Exchange:** IEProtein token holders can sell their IEProtein tokens on cryptocurrency exchanges, ensuring liquidity and additional profit potential.
- **Loyalty and Reward Programs:** IEProtein tokens can be used to incentivize clients and partners, encouraging active engagement with IMAGO.

9.3 Benefits for Intermediaries and Users

9.3.1 For Intermediaries

- **IEProtein Token Value Growth:** As the price of protein increases, the value of IEProtein tokens will also rise. IEProtein tokens already purchased can be exchanged for protein at the price at which they were bought, providing intermediaries with the opportunity for additional profit.
- **Inflation Protection:** Linking the IEProtein token price to a real product (protein) provides protection against inflation and protein price stability for clients and partners.
- **Liquidity:** The ability to sell IEProtein tokens on the secondary market ensures liquidity and access to funds at any time.

9.3.2 For Users

- **Transparency and Security:** The use of blockchain technology ensures the transparency of all transactions and protection against fraud.
- **Convenient Exchange:** A simple IEProtein token to protein exchange procedure makes the process convenient and accessible for all clients and partners.
- **Loyalty Programs:** Participation in loyalty programs allows users to gain additional benefits and bonuses for active engagement with IMAGO.

These tokenomics aspects highlight the key principles of IEProtein token distribution and usage, as well as their benefits for customers and system users. The tokenization of protein offers an innovative and reliable solution for all project participants, ensuring transparency, security, and asset value growth.

10. TECHNOLOGY

10.1 Blockchain Platforms

10.1.1 Ethereum Platform

ERC-20 Standards: IEProtein tokens will be issued according to ERC-20 standards on the Ethereum platform, ensuring their compatibility with most cryptocurrency wallets and exchanges. Ethereum is one of the most popular and reliable blockchain platforms, providing a wide range of capabilities for creating and managing smart contracts.

10.1.2 TRON Platform

TRC-20 Standards: In parallel with the use of Ethereum, IEProtein tokens will also be issued on the TRON platform according to TRC-20 standards. The TRON platform is known for its high performance and low transaction costs, making it attractive for IEProtein token issuance and operations.

10.2 Smart Contracts

10.2.1 Creation of Smart Contracts

Smart contracts will be used on both platforms to automate the process of exchanging IEProtein tokens for protein. These contracts will automatically process requests to exchange IEProtein tokens for protein, ensuring transparency and security of all transactions.

10.2.2 Exchange Conditions

Smart contracts will include exchange conditions, such as the minimum exchange amount (1 kg of protein or 1 IEProtein token) and the IMAGO obligation to fulfil the exchange within 6 months in the event of a temporary shortage of protein.

10.3 Transparency and Traceability

10.3.1 Open Transaction Ledger

All transactions will be recorded in open ledgers on the Ethereum and TRON blockchains, ensuring full transparency and the ability to track all operations. This will help prevent fraud and double spending of IEProtein tokens.

10.3.2 Reports and Analytics

Blockchain data will be easily accessible for transaction and exchange analysis, allowing for monitoring of the project's effectiveness.

10.4 Advantages of the Used Technologies

10.4.1 Security

- **Cryptographic Protection:** Blockchain uses advanced cryptographic methods to protect data and transactions, ensuring a high level of security and preventing unauthorized access to information.

- **Decentralization:** The decentralized nature of blockchain eliminates the need for central intermediaries, reducing the risk of fraud and increasing system resilience.

10.4.2 Transparency

- **Data Openness:** All data in the blockchain is publicly accessible, ensuring transparency of all operations and increasing trust from users and partners.
- **Immutability of Data:** Records in the blockchain are immutable, guaranteeing the accuracy and reliability of all data.

10.4.3 Process Automation

- **Smart Contracts:** Automation through smart contracts reduces transaction processing costs and eliminates the human factor. This speeds up processes and reduces the likelihood of errors.
- **Execution Conditions:** Smart contracts automatically execute the conditions embedded in them, ensuring accurate and timely fulfilment of all obligations.

10.4.4 Efficiency and Cost-Effectiveness

- **Cost Reduction:** The use of blockchain and smart contracts significantly reduces operational costs through automation and the elimination of intermediaries.
- **Faster Transactions:** Blockchain transactions are processed faster than traditional financial operations, increasing the overall efficiency of the system.

10.5 Operational Model

10.5.1 IEProtein Token Purchase

A buyer purchases the IEProtein token on an exchange or directly from another IEProtein token holder.

10.5.2 IEProtein Token Exchange

After purchasing the IEProtein token, the IEProtein token holder can visit the IMAGO office in person to exchange each IEProtein token for protein (1 IEProtein token = 1 kg of protein).



11. MARKET ANALYSIS

11.1 Current Market Situation

11.1.1 Growing Demand for Alternative Protein Sources



The insect protein market is rapidly developing, providing significant growth opportunities. Many companies are actively investing in insect protein production technologies, such as Protix (\$50 million), AgriProtein (\$105 million) [4], and Ynsect (\$125 million) [5].

INSECT PROTEIN MARKET



AgriTech. Alternative proteins – the trend towards meat, dairy and feed substitutes. Insects as feed. BRYAN GARNIER & Co Limited

ORGANIC FERTILIZER MARKET



Average price in Asia-Pacific - \$234 per ton



Fertilizer Market Size, By Form (Dry, Liquid), By Product (Organic, Inorganic), By Application (Agriculture, Horticulture, Gardening), Industry Analysis Report, Regional Outlook, Growth Potential, Covid-19 Impact Analysis & Forecast, 2022 – 2030
 AgriTech. Alternative proteins – the trend towards meat, dairy and feed substitutes. Insects as feed. BRYAN GARNIER & Co Limited
 Organic Fertilizers Market Size and Share Analysis by Source (Plant, Animal), Form (Solid, Liquid), Crop Type (Cereals & Grains, Oilseeds & Pulses, Fruits & Vegetables), Application (Broadcasting, Fertigation, Foliar Application) – Global Industry Demand Forecast to 2030
<https://www.pomaresearch.com/market-analysis/organic-fertilizer-market-report>
https://www.allbaba.com/product-detail/2022-High-quality-neutral-earthworm-protein_1600578023674.html?spm=a2700.galleryofferlist.normal_offer.d_title.6c3b563aP6H8W
 Organic Fertilizer Market SIZE & SHARE ANALYSIS - GROWTH TRENDS & FORECASTS UP TO 2029 Source: <https://www.mordorintelligence.com/industry-reports/global-organic-fertilizer-market>
https://www.allbaba.com/trade/search?spm=a2700.galleryofferlist.0.0.688427b1UICL&fb=&indexArea=product_en&categoryId=11502&keywords=organic-fertilizer&tab=all&page=2

11.1.2 Environmental Benefits

- **Reduced Carbon Footprint:** Insect protein production requires significant less water, land and other resources, and results in lower greenhouse gas emissions [11].
- **Resource Efficiency:** Converting chicken manure into protein, besides the high efficiency of converting raw materials into protein, significantly reduces the environmental burden by using harmful waste as a raw material, thus addressing the need for alternative disposal methods for chicken manure. [11].

11.1.3 Regulatory Recognition

In some countries, insect protein has gained regulatory recognition and approval for use in food products and animal feed, opening new market expansion opportunities [11].

- **European Union:** The EU allows the use of proteins from seven insect species, including housefly larvae, in aquaculture feed, and since July 2021, also in poultry and pig feed [22].
- **USA:** The FDA and AAFCO regulate the inclusion of insect proteins in animal feeds, recognizing black soldier fly larvae and housefly larvae as suitable for use in such feeds [11].
- **Canada:** The CFIA has approved the use of black soldier fly larvae in feeds for salmon and poultry, with other insect species potentially approved upon application [11].
- **China, South Africa, Australia, Brazil, Thailand, and Kenya:** These countries have approved the use of black soldier fly larvae protein in animal feed, with potential for including other insect species in the regulatory framework [11].

Thus, the use of insect protein, including housefly larvae, is gaining regulatory recognition worldwide, contributing to market development [22].

11.2 Competitors

11.2.1 Ynsect

A French company specializing in producing protein from insects, mainly from *Tenebrio Molitor* larvae, is actively expanding its operations and attracting significant investments to increase production.

11.2.2 Protix

A Dutch company also engaged in producing insect protein, primarily from the black soldier fly (*Hermetia illucens*), holds a strong market position due to its innovative technologies and sustainable production methods.

11.2.3 InnovaFeed

Another French company specializing in producing protein from insects, predominantly the black soldier fly (*Hermetia illucens*).

11.2.4 Challenges Faced by Competitors

All these companies use agricultural and food waste as raw materials, which is a limiting factor for scaling due to challenges in sourcing, logistics, and segregation of waste in large quantities. Another challenge is stricter regulation for proteins intended for human consumption, as their primary strategy is to transition from the animal feed market to the human food market, which involves reaching competitive prices using their technology.

Additionally, these companies use tray-based automated systems in their production, which have several disadvantages compared to bioreactor systems, such as:

- Longer processing periods
- Larger production areas required
- Less uniform raw material processing
- Higher energy consumption, primarily for excess heat disposal

11.3 Market Growth and Development Forecasts

11.3.1 Growth of the Global Insect Protein Market

The global insect protein market is expected to grow at an average annual rate of 27% over the next ten years. This growth is driven by increasing demand for alternative protein sources and rising investments in the sector [9].

11.3.2 Expansion of Production Capacities

Companies engaged in insect protein production are actively investing in expanding their production capacities. This allows for increased production volumes and meeting the growing market demand.

11.3.3 Innovations and Technological Advancements

The development of new technologies and production methods contributes to improving product quality and reducing costs, making insect protein more accessible and attractive to a wide range of consumers. Innovative approaches to process automation and production management help enhance the efficiency and sustainability of companies in this industry [8].

11.3.4 Market Expansion

Significant market expansion for insect protein is expected in the coming years. New markets, such as Asia, will play a key role in the growth of global demand. Companies will actively develop their international connections and collaborations to increase their share in the global market [10].

12. ROADMAP

12.1 Short-term Plans (6-12 months)

12.1.1 Tokenization Launch (1-3 months)

- **Development of Smart Contracts:** Creation and testing of smart contracts on the Ethereum (ERC-20) and TRON (TRC-20) platforms.

- **Token Issuance:** Issuance of tokens and their initial placement for unregulated sale in the market.
- **Marketing Campaign:** Initiating a marketing campaign to attract clients and partners and inform the public about the benefits of IEProtein tokens and the possibilities of exchanging them for products.

12.1.2 Creating Exchange Infrastructure (3-6 months)

- **Logistics Management:** Organizing logistics processes for exchanging tokens for products (protein) at the company office.
- **Employee Training:** Conducting training for employees who will handle exchange requests and customer service.

12.1.3 Initiating IEProtein Token-to-Protein Exchange (6-12 months)

- **Exchange Process Launch:** Starting to accept requests for token-to-product exchanges and ensuring timely delivery of protein.
- **Monitoring and Analysis:** Regularly monitoring exchange processes and analyzing data to improve system performance.

12.2 Long-term Plans (1-5 years)

12.2.1 Expanding Production Capacities (1-2 years)

- **Increasing Production Volumes:** Expanding production capacities to meet growing demand for products.
- **Implementing New Technologies:** Developing and implementing innovative technologies to enhance production efficiency and product quality.

12.2.2 Geographic Expansion (2-3 years)

- **Entering New Markets:** Expanding presence in international markets, such as Asia, Europe, and North America.
- **Establishing Partnerships:** Collaborating with local partners to streamline logistics and improve customer service.

12.2.3 Developing the IEProtein Token Ecosystem (3-4 years)

- **Additional Services:** Introducing new services and opportunities for token holders, such as loyalty programs, bonuses, and discounts.
- **Integration with Other Platforms:** Integrating tokens with other blockchain platforms and services to expand functionality and increase liquidity.

12.2.4 Sustainable Development and Innovations (4-5 years)

- **Eco-Sustainability:** Implementing environmentally friendly technologies and processes to minimize environmental impact.
- **New Products:** Developing and launching new types of products based on insect protein to expand the product range and meet the needs of various market segments.

12.3 Key Phases and Goals

12.3.1 Phase 1: IEProtein Token Launch and Initial Placement (0-6 months)

- **Goal:** Ensure successful IEProtein token implementation and attract protein buyers, securing product sales.
- **Result:** Creation and testing of smart contracts, unregulated sales on the exchange, and the launch of the marketing campaign.

12.3.2 Phase 2: Infrastructure Creation and Exchange Initiation (6-12 months)

- **Goal:** Organize token-to-product exchange processes and ensure their smooth operation.
- **Result:** Ensuring logistics, launching the online platform, employee training, and starting to accept exchange requests.

12.3.3 Phase 3: Expansion and Geographic Expansion (1-3 years)

- **Goal:** Increase production capacities and enter new markets.
- **Result:** Expanding production capacities, establishing international partnerships, and entering new markets.

12.3.4 Phase 4: Token Ecosystem Development and Innovations (3-5 years)

- **Goal:** Strengthen market position and continue innovative development.
- **Result:** Introducing additional services for IEProtein token holders, integrating with other platforms, implementing eco-friendly technologies, and developing new products.

13. TEAM

13.1 Key Team Members and Their Experience

13.1.1 Leonid Nikishov—Chief Executive Officer

- **Education:** National Academy of Management, Law, General Direction, Bachelor
- **Experience:** Leonid has extensive experience in management and strategic planning. His knowledge and skills enable him to effectively lead the project and achieve set goals.
- **Role in the Project:** Leonid is responsible for the overall management of the project, strategy development, and long-term planning. He represents IMAGO in international markets.
- **Achievements:**
 - Led a law firm
 - Has experience in the show business sector
 - Developed a project of new technologies in building materials
 - Headed an engineering company that developed equipment for construction, agriculture, space, and medicine

13.1.2 Viacheslav Kaptenko—Chief Technology Officer

- **Education:** Zaporizhzhia National Technical University, Mechanical Engineering, Specialist

- **Experience:** Viacheslav is an experienced specialist in R&D. He has deep knowledge in engineering mechanics, automated control systems for technological projects, biotechnology, and the creation of advanced technological equipment.
- **Role in the Project:** Viacheslav leads the technical team and is responsible for the R&D of the project. He ensures the safety and reliability of the project's technical infrastructure.
- **Achievements:**
 - Led the development of new metal-cutting machines
 - Headed the development and construction of a plant to produce building materials
 - Engaged in research and development of new construction technologies
 - Headed the development of equipment for agriculture, space, and medicine

13.1.3 Manoj Menon—Chief Financial Officer

- **Education:** Flinders University, Economics, Bachelor; University of Newcastle, Finance, International Business, MBA
- **Experience:** Manoj has extensive experience in financial management and strategic planning. His professional skills include budget management and financial analysis.
- **Role in the Project:** Manoj is responsible for financial planning and resource management of the project. He handles budgeting, financial analysis, and ensures the financial stability of IMAGO.
- **Achievements:**
 - 35 years of experience in Accounting & Finance roles gained at reputable Big 4, MNC, and international firms
 - Successfully raised over \$100M USD in his professional career
 - Currently an adjunct professor at the University of Economics Ho Chi Minh City lecturing on subjects in Finance & Accounting at the Bachelor & master's levels

13.1.4 Maria Rasputina—Chief Marketing Officer

- **Education:** Lipetsk State Technical University, Humanities and Social Sciences, Sociology, Master; Regional Financial-Economic Institute, Economics, Accounting and Auditing, Master
- **Experience:** Maria has over 16 years of experience in marketing across different countries. For the last 5 years, she has specialized in agricultural innovations, making her an expert in implementing new technologies in this sector. She has a wealth of experience in developing marketing strategies and managing large international projects.
- **Role in the Project:** Maria is responsible for developing and implementing the marketing strategy for IMAGO Engineering. She coordinates all marketing activities, including the product portfolio and market expansion. Her task is to ensure brand recognition and support the successful launch of

IEProtein tokens globally. Maria plays a key role in shaping IMAGO image and promoting its innovative solutions in agriculture.

- **Achievements:**
 - Served as Marketing Director for several corporations
 - Led the innovation department in an agricultural corporation
 - Conducted research and analysis of new startups for corporate development

13.1.5 G. Mark Sooria Kumar—Deputy Director—Advisor

- **Education:** University of Bath, Business Management and Public Relations
- **Experience:** Mark has significant experience in consulting and strategic planning. His knowledge helps in developing effective solutions and supporting the team.
- **Role in the Project:** Mark advises the team on strategic issues and provides support in making key decisions. He plays an important role in developing and implementing the project's strategy.
- **Achievements:**
 - 25 years of experience in Public Relations for Regional and International Projects
 - Successfully implemented international projects in cybersecurity, property development, and oil & gas

13.1.6 Mohamad Johan—Regional Director

- **Education:** SEGi University in collaboration with the University of Sunderland, Business Management, Bachelor; SEGi University and Colleges, Foundations in Commerce
- **Experience:** Mohamad has extensive experience in managing regional projects and coordinating international activities. His skills help in the successful implementation of projects in various markets.
- **Role in the Project:** Mohamad is responsible for coordinating and managing projects in different regions. He ensures effective interaction between regional teams and supports the successful execution of projects and communication between departments.

- **Achievements:**
 - Experienced in successfully managing over 100 employees within large sales and manufacturing corporations in Malaysia

14. CONCLUSION

14.1 Summary of Key Points

This document has covered the main aspects of tokenizing the product – protein, produced by "IMAGO Engineering SDN. BHD."

14.2 Key Highlights Include

14.2.1 Token-to-Real Product Linkage

Each IEProtein token is equivalent to 1 kg of protein, ensuring simplicity and transparency in calculations for partners, clients and intermediates. At the time of IEProtein token issuance price of 1 kg of protein is 2 USD.

14.2.2 IEProtein Token Exchange Process

IEProtein token holders can exchange their IEProtein tokens for protein by visiting IMAGO office. The minimum exchange quantity is 1 kg (1 kg of IMAGO protein per 1 IEProtein token).

14.2.3 Transparency and Security

The use of blockchain technologies (Ethereum and TRON) ensures the transparency of all transactions and protection against fraud. Smart contracts automate the exchange processes, ensuring precise and timely fulfilment of all obligations.

14.2.4 Flexibility and Increasing IEProtein Token Value

The price of the IEProtein token will increase in proportion to the price of 1 kg of protein, providing protection against inflation and potential asset value growth.

14.2.5 Project Team

Key team members possess the necessary skills and experience for the successful implementation and sustainable development of IMAGO.

14.3 Importance of the Proposed Solution and Its Advantages

14.3.1 Sustainable Growth and Development

Tokenizing protein products allows IMAGO to take a leading position in the market for alternative protein sources. With the growing global demand for sustainable and environmentally friendly products, IMAGO offers significant opportunities for expansion and strengthening market positions.

14.3.2 Increased Trust and Customer Loyalty

The transparency and security of transactions ensured by blockchain technologies increase trust among customers and partners. Loyalty programs and the ability to exchange IEProtein tokens for real products encourage repeat purchases and strengthen customer commitment to the brand.

14.3.3 Market Attractiveness

Linking the IEProtein token value to real products makes it less susceptible to the volatility typical of other cryptocurrencies. This makes IEProtein tokens an attractive payment instrument, ensuring stability in purchasing strategies for consumers and intermediaries.

14.3.4 Environmental and Economic Sustainability

Producing protein from insects requires significantly fewer resources and has a lower environmental impact compared to traditional protein sources. This aligns with global trends towards sustainable development and environmentally friendly production processes.

14.3.5 Automation and Process Efficiency

Using smart contracts automates the exchange processes and reduces operational costs. This speeds up transactions, decreases the likelihood of errors, and increases the overall efficiency of the system.

These key points underscore the significance and advantages of the proposed solution. Tokenizing protein products represents an innovative and sustainable approach that not only improves current processes but also opens new business opportunities. The project has high growth and development potential, ensuring long-term value for all participants.

15. LEGAL STATEMENTS AND NOTICES

15.1 Notice to residents of the United States

15.1.1 IEProtein tokens described in this White Paper have not been and will not be registered under the Securities Act of 1933, as amended ("U.S. Securities Act"), or any state securities laws. IEProtein tokens are not offered or sold within the United States or to, or for the account or benefit of, United States persons (as defined under the U.S. Securities Act). The IMAGO tokens may not be offered, sold, resold, transferred, or delivered, directly or indirectly, in the United States or to United States persons.

15.2 Notices to residents of Malaysia

15.2.1 IEProtein tokens are not securities as defined under the Capital Markets and Services Act 2007, as amended ("CMSA"). Accordingly, the CMSA does not apply to the issuance of IEProtein tokens. For the avoidance of doubt, the offering of IEProtein tokens need not be accompanied by any prospectus or profile statement, and no prospectus or profile statement needs to be lodged with the Securities Commission Malaysia ("SCM").

15.2.2 This White Paper does not constitute an offer of, or an invitation to purchase, IEProtein tokens in any jurisdiction where such offer or sale would be unlawful. No regulatory authority in Malaysia, including the SCM, has reviewed, approved, or disapproved of IEProtein tokens or this White Paper. This White Paper, or any part hereof, may not be distributed or disseminated in any jurisdiction where offering IEProtein tokens as set out in this White Paper is regulated or prohibited.

- 15.2.3** This offering does not constitute an initial exchange offering as defined under the Guidelines on Digital Assets, first issued on 28 October 2020 by the SCM pursuant to section 377 of the CMSA. This document is not a prospectus or an offering document of any kind and is not intended to constitute an offer of securities or a solicitation for investment in securities in Malaysia. The words "invest," "investing," "investment," "investor," and similar expressions are used in this White Paper solely for illustrative purposes. They do not signify, represent, or imply any form of investment relationship between IMAGO and IEProtein token holders. They should not be interpreted as an offer or solicitation for investment, nor should they be construed as creating any form of legal or financial relationship typically associated with investments. IEProtein tokens are not intended to confer any rights to profits, dividends, or other financial returns, and holding IEProtein tokens does not equate to holding a stake in IMAGO or any of its affiliates. This offering is not conducted through any recognized market operator or exchange registered with the SCM.
- 15.2.4** Prospective purchasers of IEProtein tokens are advised to consult their own legal and financial advisers to ensure that this offering complies with the laws of Malaysia, including, but not limited to, the CMSA.
- 15.2.5** Upon receiving any IEProtein tokens, you will be deemed to have reviewed this White Paper (and any information requested and obtained from IMAGO) in full and to have agreed to the terms of this offering, including the fact that this offering does not fall within the scope of any securities laws in Malaysia, including the CMSA, and is not regulated by the SCM. You further acknowledge and agree that IEProtein tokens are not securities and are not intended to generate any form of investment return.

15.3 Notices to residents of Singapore

- 15.3.1** IEProtein tokens described in this White Paper are not intended to constitute securities under the Securities and Futures Act (Cap. 289) ("SFA"). This document does not constitute a prospectus as defined under the SFA and has not been registered as a prospectus with the Monetary Authority of Singapore. IEProtein tokens may not be offered or sold, nor may any document or other material in connection with IEProtein tokens be distributed, directly or indirectly, to persons in Singapore except pursuant to exemptions provided in the SFA. Prospective purchasers of IEProtein tokens should consult their own legal and financial advisers regarding the compliance of this offering with the laws of Singapore.

15.4 Notices to residents of the European union

15.4.1 IEProtein tokens described in this White Paper are not intended to constitute securities under Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003 on the prospectus to be published when securities are offered to the public or admitted to trading, and amending Directive 2001/34/EC. This document does not constitute a prospectus or any other type of offering document and is not intended to constitute an offer of securities or a solicitation for investment in securities in any member state of the European Union. Prospective purchasers of IEProtein tokens should consult their own legal and financial advisers regarding the compliance of this offering with the laws of the European Union and its member states.

15.5 Notices to residents of the Russian federation

15.5.1 The information contained in this White Paper is not an offer or an invitation to make offers to sell, purchase, exchange, or otherwise transfer securities or foreign financial instruments in the Russian Federation to or for the benefit of any Russian person, except "qualified investors" (as defined under Russian securities laws) to the extent permitted under Russian securities laws. This document is not an advertisement in connection with the "placement" or "public circulation" (as both terms are defined under Russian securities law) of any securities, and any financial instruments described herein are not intended for "placement" or "public circulation" in the Russian Federation, unless otherwise permitted under Russian securities laws. Neither any financial instruments described in this White Paper nor a prospectus relating to such financial instruments has been or will be registered with the Russian Central Bank. Prospective purchasers of IEProtein tokens should consult their own legal and financial advisers regarding the compliance of this offering with the laws of the Russian Federation.

15.6 General notices

15.6.1 This White Paper does not constitute an offer to sell or a solicitation of an offer to buy IEProtein tokens in any jurisdiction where such offer or solicitation would be unlawful. The information in this document is provided for informational purposes only and is subject to change without notice. Prospective purchasers of IEProtein tokens are advised to consult their own legal, tax, and financial advisers before making any investment decisions.

15.6.2 The information in this White Paper is current only as of the date on the cover. After this date, the information, including details concerning business operations and financial condition of IMAGO,

may have changed. Neither the delivery of this White Paper nor any sale made in connection with this offering shall constitute a representation that no such changes have occurred. IMAGO does not make, and hereby disclaims, any representation, warranty, undertaking, or other assurance in any form whatsoever to any person regarding the truth, accuracy, or completeness of any information in this White Paper.

- 15.6.3** Whether taken or read as a whole or in part, this White Paper is not, and should not be regarded as, any form of legal, financial, tax, or other professional advice. You should seek independent professional advice before making your own decision as to whether or not to receive any IEProtein tokens. You are responsible for any and all evaluations, assessments, and decisions you make regarding investing in IEProtein tokens. You may request additional information from IMAGO related to this offering. IMAGO may, but is not obligated to, disclose such information based on whether (i) it is legal to do so and (ii) the requested information is reasonably necessary to verify the information contained in this White Paper.
- 15.6.4** IMAGO is not responsible for compelling any person to accept any IMAGO tokens and disclaims, to the fullest extent permitted by law, any and all liability for any adverse consequences arising out of or in relation to the rejection of the IMAGO tokens.
- 15.6.5** IEProtein tokens and any related services provided by IMAGO (if any) are provided on an "as is" and "as available" basis. IMAGO does not grant any warranties or make any representations, express or implied, regarding the accessibility, quality, suitability, accuracy, adequacy, or completeness of IEProtein tokens or any related services provided by IMAGO. IMAGO expressly disclaims any and all liability for errors, delays, or omissions, or for any and all actions taken in reliance on IEProtein tokens and related services. No warranty, including non-infringement of third-party rights, title, merchantability, satisfactory quality, or fitness for a particular purpose, is given in conjunction with IEProtein tokens and any related services provided by IMAGO.

15.7 Risk factors

15.7.1 Regulatory risks

The regulation of tokens such as IEProtein tokens is still in a very nascent stage of development in Malaysia. There is a high degree of uncertainty regarding how tokens and token-related activities will be treated. The applicable legal and regulatory framework may change after the issuance date of this White Paper. Such changes may be rapid, and it is not possible to anticipate the nature of such legal and regulatory evolution. IMAGO does not, in any way, represent that the status of IEProtein tokens will remain unaffected

by any legal or regulatory changes at any time before, during, or after this offering.

15.7.2 No legal remedy

Bank Negara Malaysia ("Bank") does not recognize digital tokens such as IEProtein tokens as legal tender or as a form of payment instrument regulated by the Bank. Consequently, the Bank will not provide any avenues of redress for aggrieved IMAGO token holders.

15.7.3 No regulatory supervision

Neither IMAGO nor its affiliates are currently regulated or subject to the supervision of any regulatory body in Malaysia. In particular, IMAGO and its affiliates are not registered with the SCM as any type of regulated financial institution or financial or investment adviser and are not subject to the standards imposed upon such persons under any securities laws in Malaysia, including the Malaysian Capital Markets Act, and other related regulatory instruments. Such persons are required to comply with various requirements and standards concerning disclosures, reporting, compliance, and the conduct of their operations to maximize investor protection. Since IMAGO is not subject to such requirements or standards, it will make decisions on these issues at its own discretion. While IMAGO will consider best practices on these issues, holders of IEProtein tokens may not enjoy the same extent and degree of investor protections as they would with regulated entities.

15.7.4 No fiduciary duties owed

As IMAGO is not a regulated financial institution or financial or investment adviser, it does not owe investors in IEProtein tokens any fiduciary duties. This means that IMAGO has no legal obligation to always act in good faith in the best interests of IEProtein token holders. While IMAGO will consider the interests of IMAGO token holders, it may also consider the interests of other key stakeholders and may prefer these interests over those of IEProtein token holders. This may result in decisions that conflict with the interests of IEProtein token holders. Not owing any fiduciary duties means that IEProtein token holders may have limited rights of recourse against IMAGO and its affiliates in the event of disputes.

15.7.5 Tax risks

The tax characterization of the IEProtein tokens is unclear. Accordingly, the tax treatment is uncertain. All persons who wish to receive IEProtein tokens should seek independent tax advice before deciding whether to receive any IEProtein tokens. IMAGO does not make any representation regarding any tax consequences arising from purchasing or holding any IEProtein tokens.

15.7.6 Risks from third parties

The tokenized nature of the IEProtein tokens means that they are a blockchain-based asset. The security, transferability, storage, and accessibility of blockchain assets depend on factors outside IMAGO's control, such as the security, stability, and suitability of the underlying blockchain (in this case, the

Ethereum blockchain), mining attacks, and who has access to the smart contract where the IEProtein tokens are stored. IMAGO cannot assure that it can prevent such external factors from having a direct or indirect adverse impact on the IEProtein tokens. Persons intending to receive the IEProtein tokens should note that adverse events caused by such external factors may result in the loss of some or all of the IEProtein tokens. Such loss may be irreversible. IMAGO is not responsible for taking steps to retrieve any IEProtein tokens lost in this manner.

15.7.7 Risks in receiving the IMAGO tokens

IMAGO cannot and does not guarantee or otherwise assure that there are no risks related to the issuance of the IEProtein tokens. The IEProtein tokens may involve third parties or external platforms (e.g., wallets), introducing risks that would not otherwise be present, such as misconduct or fraud by the third party, or failure to receive the IEProtein tokens upon payment due to a third-party wallet's incompatibility. IMAGO is not responsible for any risks arising from the involvement of third parties, including the risk of not receiving or subsequently losing any or all IEProtein tokens issued to you.

15.8 Right to redeem IMAGO tokens

IMAGO reserves the right to redeem the issued IEProtein tokens from their holders at any time after five years from their issuance date at the current market price. This provision provides additional flexibility and control over the number of IEProtein tokens in circulation and supports the stability of the token market.

15.9 Right to amend this white paper

IMAGO reserves the right to unilaterally amend and supplement this White Paper. The current version of this White Paper can always be found on the official website of IMAGO company, www.imagoengineering.com.

16. REFERENCES

To ensure the accuracy and completeness of the information presented in this White Paper, the following sources and studies were utilized:

16.1 Research on the Insect Protein Market

[1] Tokenization in Agriculture: Transforming Agribusiness and Food Supply - TheDailyGuardian

[2] Transforming Food Supply Chains with Token Development Services (rwaltz.com)

[3] Revolutionizing Commodity Trading with Tokenization and Smart-Contracts (linkedin.com)

[4] Insect Protein Market Size, Scope & Growth Opportunities By 2031 (databridgemarketresearch.com)

[5] Insect Protein Market Size, Share, Growth | Report [2022-2029]
(fortunebusinessinsights.com)

[6] Revolutionizing Food Consumption: Insect Protein Emerges as
(globenewswire.com)

[7] Insect Protein Market Report: Trends, Forecast and Competitive Analysis
(lucintel.com)

[8] Insect Protein Market Size, Share | CAGR of 31.10%

[9] Yahoo входит в семейство брендов Yahoo.

[10] Insect Protein Market Size, Share, Growth | Report [2022-2029]
(fortunebusinessinsights.com)

[11] Insect Protein Market Size, Scope & Growth Opportunities By 2031
(databridgemarketresearch.com)

[12] Insect Protein Market Size, Share | CAGR of 31.10%

[13] AgriTech. Alternative proteins – the trend towards meat, dairy and feed
substitutes. Insects as feed. BRYAN GARNIER & Co Limited

[14] Fertilizer Market Size, By Form (Dry, Liquid), By Product (Organic, Inorganic), By
Application (Agriculture, Horticulture, Gardening), Industry Analysis Report, Regional
Outlook, Growth Potential, Covid-19 Impact Analysis & Forecast, 2022 – 2030

[15] AgriTech. Alternative proteins – the trend towards meat, dairy and feed
substitutes. Insects as feed. BRYAN GARNIER & Co Limited

[16] Organic Fertilizers Market Size and Share Analysis by Source (Plant, Animal),
Form (Solid, Liquid), Crop Type (Cereals & Grains, Oilseeds & Pulses, Fruits &
Vegetables), Application (Broadcasting, Fertigation, Foliar Application) – Global
Industry Demand Forecast to 2030 [https://www.psmarketresearch.com/market-](https://www.psmarketresearch.com/market-analysis/organic-fertilizers-market-report)
[analysis/organic-fertilizers-market-report](https://www.psmarketresearch.com/market-analysis/organic-fertilizers-market-report)

[17] [https://www.alibaba.com/product-detail/2022-High-quality-neutral-earthworm-](https://www.alibaba.com/product-detail/2022-High-quality-neutral-earthworm-protein_1600578023674.html?spm=a2700.galleryofferlist.normal_offer.d_title.6c3b563eP6H8rW)
[protein_1600578023674.html?spm=a2700.galleryofferlist.normal_offer.d_title.6c3b5](https://www.alibaba.com/product-detail/2022-High-quality-neutral-earthworm-protein_1600578023674.html?spm=a2700.galleryofferlist.normal_offer.d_title.6c3b563eP6H8rW)
[63eP6H8rW](https://www.alibaba.com/product-detail/2022-High-quality-neutral-earthworm-protein_1600578023674.html?spm=a2700.galleryofferlist.normal_offer.d_title.6c3b563eP6H8rW)

[18] Organic Fertilizer Market SIZE & SHARE ANALYSIS - GROWTH TRENDS &
FORECASTS UP TO 2029

[19] [https://www.alibaba.com/trade/search?spm=a2700.galleryofferlist.0.0.68842fb1](https://www.alibaba.com/trade/search?spm=a2700.galleryofferlist.0.0.68842fb1hUICJL&fsb=y&IndexArea=product_en&categoryId=11502&keywords=organic+fertilizer&tab=all&page=2)
[hUICJL&fsb=y&IndexArea=product_en&categoryId=11502&keywords=organic+fertiliz](https://www.alibaba.com/trade/search?spm=a2700.galleryofferlist.0.0.68842fb1hUICJL&fsb=y&IndexArea=product_en&categoryId=11502&keywords=organic+fertilizer&tab=all&page=2)
[er&tab=all&page=2](https://www.alibaba.com/trade/search?spm=a2700.galleryofferlist.0.0.68842fb1hUICJL&fsb=y&IndexArea=product_en&categoryId=11502&keywords=organic+fertilizer&tab=all&page=2)

16.2 Technical Aspects of Blockchain Technologies

[20] <https://www.emerald.com/insight/content/doi/10.1108/978-1-83982-198-120211006/full/html>

[21] <https://www.nist.gov/publications/blockchain-technology-overview>

16.3 Regulatory and Legal Aspects

[22] [Sustainable Food Systems: EU Regulatory Framework and Contribution of Insects to the Farm-To-Fork Strategy | Request PDF \(researchgate.net\)](#)

[23] [Alternative proteins and EU food law - ScienceDirect](#)

16.4 Marketing and Business Strategies

[24] <https://blog.sagipl.com/ieo-ido-sto-and-defi-marketing-strategies/>

[25] <https://press.farm/ieo-ido-sto-and-defi-marketing-strategy/>